Kempen & Co appoints Jan De Kerpel as Managing Director Life Sciences

Jan De Kerpel is appointed as the new Managing Director Life Sciences & Healthcare at Kempen & Co. Life Sciences is a very important expertise within Kempen & Co, next to real estate, fintech and Benelux shares. De Kerpel is responsible for leading and further expanding the Life Sciences & Healthcare franchise that focuses on European IPOs, capital market transactions, M&A and financial advice.

Dr. Jan De Kerpel has a wealth of experience in the Life Sciences sector. For almost ten years, he worked as a life science specialist at KBC Securities, where he was proclaimed best biotech analyst in Europe three times by the Financial Times. He played a key role in raising more than 1 billion euros for several life sciences companies. In addition, De Kerpel was employed in the sector itself at organizations such as Tibotec (now part of Johnson&Johnson) and Devgen.


Jan De Kerpel is pleased with his appointment: “Life Sciences is an important sector within Kempen. The Corporate Finance team has a long history of successfully realized M&A and ECM transactions for our clients in the European market. Our experienced team, with both backgrounds in life sciences and in finance, is one of the largest in Europe. I look forward to further expanding our leading position.”


Last week, De Kerpel and his team placed new shares to European institutional investors for Mithra Pharmaceuticals, a company specializing in women’s medicine. In addition, they have been involved in the recent NASDAQ IPO of the Belgian argenx and a capital market transaction of the French Nanobiotix.



Interested in a regular update of the Life Sciences and biotech sector in Flanders?